| SVATON, Martin, Monika BRATOVÁ, Leona KOUBKOVA, Ondrej FISCHER, Bohuslav MELICHAR, Michal HRNCIARIK, Daniel DOLEZAL, Ondrej BILEK, Jana KREJCI, Marie DROSSLEROVA, Zdenka DLOUHA, Jiri BLAZEK, Petra MAJKOVA, Lucie BROŽOVÁ and Marek STASTNY. Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer? Anticancer Research. Athens: International Institute of Anticancer Research, 2022, vol. 42, No 4, p. 1987-1995. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.15677. |
Other formats:
BibTeX
LaTeX
RIS
@article{1863072,
author = {Svaton, Martin and Bratová, Monika and Koubkova, Leona and Fischer, Ondrej and Melichar, Bohuslav and Hrnciarik, Michal and Dolezal, Daniel and Bilek, Ondrej and Krejci, Jana and Drosslerova, Marie and Dlouha, Zdenka and Blazek, Jiri and Majkova, Petra and Brožová, Lucie and Stastny, Marek},
article_location = {Athens},
article_number = {4},
doi = {http://dx.doi.org/10.21873/anticanres.15677},
keywords = {NSCLC; lung cancer; nivolumab; chemotherapy; overall survival; pemetrexed; taxanes; vinorelbine},
language = {eng},
issn = {0250-7005},
journal = {Anticancer Research},
title = {Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?},
url = {https://ar.iiarjournals.org/content/42/4/1987},
volume = {42},
year = {2022}
}
TY - JOUR
ID - 1863072
AU - Svaton, Martin - Bratová, Monika - Koubkova, Leona - Fischer, Ondrej - Melichar, Bohuslav - Hrnciarik, Michal - Dolezal, Daniel - Bilek, Ondrej - Krejci, Jana - Drosslerova, Marie - Dlouha, Zdenka - Blazek, Jiri - Majkova, Petra - Brožová, Lucie - Stastny, Marek
PY - 2022
TI - Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
JF - Anticancer Research
VL - 42
IS - 4
SP - 1987-1995
EP - 1987-1995
PB - International Institute of Anticancer Research
SN - 02507005
KW - NSCLC
KW - lung cancer
KW - nivolumab
KW - chemotherapy
KW - overall survival
KW - pemetrexed
KW - taxanes
KW - vinorelbine
UR - https://ar.iiarjournals.org/content/42/4/1987
N2 - Aim: This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens. Patients and Methods: The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treated adenocarcinomas in second and higher lines of treatment. In relation to objective response rate, progression-free interval, and overall survival, three comparisons of patient were made: A: Those treated in first line with cisplatin and pemetrexed versus carboplatin with paclitaxel or vinorelbine; B: treatment with cisplatin and pemetrexed versus carboplatin with paclitaxel/vinorelbine and bevacizumab; and C: treatment in previous lines with pemetrexed (first-line cisplatin and pemetrexed plus those treated in second line with pemetrexed) versus treatment with taxane (first-line carboplatin and paclitaxel only plus those treated with second-line docetaxel). Results: We observed no differences in objective response rate or progression-free survival between patients treated with the stated chemotherapeutic regimens. We observed a trend towards better overall survival for patients treated with carboplatin plus taxanes or vinorelbine with/without bevacizumab. Conclusion: From our overall survival data, a chemotherapeutic regimen of carboplatin plus taxanes or vinorelbine with/without bevacizumab might be a better partner for immunotherapy than a cisplatin and pemetrexedbased one.
ER -
SVATON, Martin, Monika BRATOVÁ, Leona KOUBKOVA, Ondrej FISCHER, Bohuslav MELICHAR, Michal HRNCIARIK, Daniel DOLEZAL, Ondrej BILEK, Jana KREJCI, Marie DROSSLEROVA, Zdenka DLOUHA, Jiri BLAZEK, Petra MAJKOVA, Lucie BROŽOVÁ and Marek STASTNY. Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer? \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2022, vol.~42, No~4, p.~1987-1995. ISSN~0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.15677.
|
